You just read:

Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

News provided by

Blueprint Medicines

Aug 07, 2019, 08:00 ET